Merck drug shows promise in bladder cancer

September 29, 2014 1:50 PM

6 0

Merck drug shows promise in bladder cancer

KEYTRUDA is suggested for use in the U.S. at a dose of 2 mg/kg every three weeks to help treat patients with unrespectable or metastatic melanoma and disease progression.

Merck announced the initial presentation of data on the investigational use of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in PD-L1 positive, advanced urothelial cancer, otherwise known as bladder cancer. Results from the early findings indicated a confirmed overall 24 percent response rat...

Also read: Intel reports better-than-expected earnings as data center chips grow 13% to $4.5 billion

Read more

To category page